Physician profile
Emmanuel Y Chang
NPI 1083877740
$253,769.13
in general payments reported to CMS, 2019-2025
26 companies · $31K in 2025
The $31K reported for 2025 was more than what 96% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $13K · 2021: $36K · 2022: $54K · 2023: $43K · 2024: $53K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Consulting Fee: $46K · Travel and Lodging: $10K · Food and Beverage: $8,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,838.93 |
| Consulting Fee | $46,032.50 |
| Travel and Lodging | $10,422.09 |
| Food and Beverage | $8,415.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $141,619.78 | 2019-2025 | Vabysmo, Susvimo, Lucentis |
| Bausch & Lomb Americas INC. | $43,859.29 | 2022-2025 | Stellaris, Stellaris Elite, Xipere |
| Regeneron Healthcare Solutions, INC. | $34,023.87 | 2019-2025 | Eylea Hd, Eylea |
| Novartis Pharmaceuticals Corporation | $20,027.75 | 2019-2022 | |
| Carl Zeiss Meditec USA, INC. | $4,449.37 | 2025 | Cirrus Hd-Oct, Clarus, Atlas 500 |
| Regeneron Pharmaceuticals, INC. | $3,857.64 | 2020-2023 | Eylea |
| US Retina LLC | $2,184.51 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $569.48 | 2022-2025 | Syfovre |
| Allergan, INC. | $492.97 | 2019-2021 | |
| Astellas Pharma US INC | $415.04 | 2023-2025 | Izervay |
| Genentech, INC. | $400.97 | 2019-2024 | Vabysmo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $350.97 | 2019-2021 | |
| Abbvie INC. | $321.72 | 2023-2025 | Ozurdex |
| Harrow Eye, LLC | $243.99 | 2023-2025 | Iheezo |
| Biogen, INC. | $200.41 | 2022-2024 | Byooviz |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $183.48 | 2022-2023 | |
| Optos, INC. | $105.17 | 2019 | |
| Sun Pharmaceutical Industries INC. | $101.90 | 2019-2020 | |
| Alcon Vision LLC | $100.35 | 2023 | Constellation |
| Oculus Surgical INC. | $86.82 | 2023 | |
| Carl Zeiss Meditec, INC. | $69.76 | 2019 | |
| Alimera Sciences, INC. | $38.36 | 2019-2023 | Iluvien |
| Dutch Ophthalmic, USA | $38.29 | 2022 | |
| Springworks Therapeutics, INC. | $27.24 | 2025 | Gomekli |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$45,684.20 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.